The trial will compare the safety and efficacy of equecabtagene autoleucel versus standard therapies in r/r MM patients.
Morning Overview on MSN
Japan approves world-first iPSC therapy for Parkinson’s disease
Japan’s health ministry has endorsed the first stem-cell therapy derived from induced pluripotent stem cells (iPSCs) for ...
Japan has approved two stem cell-based therapies for treating Parkinson's disease and heart failure in a world first, through ...
Cellares is advancing the global expansion of its state-of-the-art automated cell therapy manufacturing platform. The company announced May 29, in collaboration with Mitsui Fudosan, the establishment ...
Here is a fact that should reframe how you think about Insmed (NASDAQ:INSM) and its lung disease franchise: Japan has more ...
An innovative stem cell therapy approved for severe heart failure has been cleared for use in Japan. Here is why it matters ...
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Japan Patent Office has fully ...
Takeda Pharmaceutical has a decadeslong history in plasma-derived therapies, but the company is far from done expanding its reach in the field. And the drugmaker's next project is its largest yet in ...
– Daiichi Sankyo to Transfer Yescarta Marketing Authorization in Japan to Gilead Sciences K.K. – – Kite Cell Therapy Business Unit at Gilead Sciences K.K. Will Manage the Sales and Promotion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results